Novartis’ randomized, double-blind, placebo-controlled CAN-COVID trial failed to meet endpoints
On Nov. 5, 2020, Novartis announced data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
Gilead Sciences signed joint procurement agreement with European Commission for Vekluryï¾® (remdesivir)
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
RedHill Biopharma opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
OpGen announced completion of study collaboration with Karolinska Institutet on bacterial co-infections in COVID-19 pneumonia patients
On Sept. 28, 2020, OpGen announced the successful completion of the clinical study between its subsidiary, Curetis, and…
Brazil approved RedHill Biopharma’s phase 2/3 COVID-19 study with opaganib
On Sept. 22, 2020, RedHill Biopharma announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing…
Roche’s phase III EMPACTA study showed reduced likelihood of ventilation in hospitalised patients with COVID-19 associated pneumonia
On Sept. 17, 2020, Roche announced that the phase III EMPACTA study met its primary endpoint, showing that…
Text analysis software track global biothreats, such as COVID-19
On Sept. 14, 2020, at the Pacific Northwest National Laboratory (PNNL) reported that U.S. analysts monitoring global biothreats…
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
Gileadï¾’s investigational antiviral Vekluryï¾® (remdesivir) received FDA Emergency Use Authorization for treatment of patients with moderate COVID-19
On Aug. 28, 2020, Gilead Sciences announced the FDA expanded the Emergency Use Authorization (EUA) enabling use of…
RedHill Biopharma Announced Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…
Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19
On Aug. 27, 2020, Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19 from our CLIA-certified laboratory….
Largest global study on hydroxychloroquine safety finds increased cardiovascular risk with azithromycin
On Aug. 24, 2020, the combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including…
Experimental COVID-19 vaccine prevented severe disease in mice
On Aug. 19, 2020, an experimental vaccine was reported to be effective at preventing pneumonia in mice infected…
Vanda Pharma’s interim analysis from ODYSSEY study showed tradipitant may accelerate clinical improvement in patients with COVID-19 pneumonia
On Aug. 18, 2020, Vanda Pharma reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2…
RedHill Biopharma’s phase 2/3 COVID-19 study approved in Mexico
On Aug. 6, 2020, RedHill Biopharma announced approval from the Mexican Federal Committee for the Protection against Sanitary…
RedHill Biopharma initiated global phase 2/3 study for COVID-19
On Jul. 30, 2020, RedHill Biopharma announced that it has initiated a global Phase 2/3 clinical study evaluating…
Roche updated phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
On Jul. 29, 2020, Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)…
RedHill Biopharma accelerated phase 2/3 COVID-19 program with addition of Brazil and Mexico
On Jul. 22, 2020, RedHill Biopharma announced that it had submitted a Clinical Trial Application (CTA) with the…
RedHill Biopharma received approval for phase 2/3 COVID-19 study in Russia
On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for…
BioAegis received approval to proceed with phase 2 trial of its gelsolin COVID-19 treatment
On Jul. 15, 2020, BioAegis Therapeutics announced that it received regulatory clearance from The Spanish Agency for Medicines…
Rigel announces investigator-sponsored trial of fostamatinib in patients with COVID-19 pneumonia
On Jul. 14, 2020, Rigel Pharmaceuticals announced the initiation of an investigator-sponsored tria being conducted by Imperial College…
Pneumonia vaccine price dropped dramatically for lower-income countries thanks to the Gavi pneumococcal Advance Market Commitment
On Jun. 16, 2020, lower-income countries across the world have access life-saving pneumococcal conjugate vaccines, which protect against…
Mayo Clinic Study of Humanigen’s lenzilumab showed rapid recovery and discharged in severe and critical COVID-19 patients
On Jun. 15, 2020, Humanigen announced data on the first clinical use of lenzilumab in 12 COVID-19 patients….
RedHill Biopharma submited COVID-19 clinical trial application for phase 2/3 study with Opaganib in Russia
On Jun. 10, 2020, RedHill Biopharma announced it had submitted a Clinical Trial Application (CTA) with the Ministry…
OpGen released preliminary data demonstrating Unyvero HPN panel for pneumonia identified life-threatening bacterial co-infections in COVID-19 patients
On Jun. 9, 2020, OpGen announced preliminary data from an investigator initiated collaboration with Karolinska Institutet, Stockholm, Sweden,…
The FDA approved antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
On Jun. 4, 2020, the FDA approved Merck’s Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired…
Roche initiated initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
On Jun. 4, 2020, Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)…